Axis I: Development and characterization of in vivo cancer models
The major objective of this R&D project is to setup new experimental models of xenografted mice and rats based on the use of two regulatory sources of human primary tumor tissues. These new models will also be characterized by proteomic and genomic analysis or by target expression analysis using immunohistochemistry in tissue arrays.
|
Axis II: Research of new imaging biomarkers of activity
This R&D project aims to provide solutions to problems that are encountered during clinical trials when using novel anticancer targeted therapies: clinicians need to have access to relevant and early biomarkers of activity of new compounds and to determine the active biological dose of a novel therapy. The use of imaging techniques that are directly usable in the clinic, such as MRI/MRS, allow for better elucidation of the mechanism of action and potential of activity of novel therapies.
|
Axis III: Innovative target identification
Oncodesign is involved in the FP6 with European academic laboratories in the Plurigen project. This axis is based on various collaborations that aim to identify innovative targets implicated in proliferation or apoptosis. When a target has been identified, Oncodesign is in charge of its validation using its original target validation platform.
|
Home
Back
Top